Fujisawa Pharmaceutical

Research Laboratories, Fujisawa Pharmaceutical Company, Ltd., Yodogawa-Ku, Osaka 532, Japan. 

Case Study Development of Istodax (romidepsin, NSC 630176, depsipeptide), Fujisawa Pharmaceutical Co. 

Fig. 3 Structures of the early HDAC inhibitors—identified as HDAC inhibitors in the time frame 1977 to 1998. (n-Butyrate MIT, TSA Univ. of Tokyo, TPX Univ. of Tokyo, FR901228/FK-228 Fujisawa Pharmaceutical Co., and Univ. of Tokyo)...

Adenosine deaminase catalyzes the hydrolytic deamination of adenosine and 2 -deoxyadenosine to inosine and 2 -deoxyinosine respectively. Inhibition of adenosine deaminase leads to an accumulation of its substrates which results in adenosine receptor-mediated effects. Most inhibitors are not reported to have antinociceptive properties, but 2 -deoxycoformycin was proven to have an inhibitory effect on pain transmission (Poon and Sawynok, 1999), and Fujisawa Pharmaceuticals claim adenosine deaminase inhibitors to be active against chronic pain. 

Akahane, A. et al.(Fujisawa Pharmaceutical Corporation, Ltd) Pyrazoiopyrazines and their use as adenosine antagonists, WO 0140230, Pyrazoiopyrazines as adenosine antagonists, WO 0024742. 

Tsuji, K., Terasaka, T., Nakamura, K. (Fujisawa Pharmaceuticals Corporation, Ltd.) Imidazole compounds and their use as adenosine deaminase inhibitors, WO 0153271. 

Soneoka, K., Shuto, H., Fujii, T. (Fujisawa Pharmaceutical Co., Ltd., Japan) Use of peptides for the manufacture of a medicament for treatment of chronic obstructive pulmonary disease, mental disease, ond other diseases, WO9420126. 

---